<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799873</url>
  </required_header>
  <id_info>
    <org_study_id>CORSAAR-AAT-001</org_study_id>
    <nct_id>NCT04799873</nct_id>
  </id_info>
  <brief_title>Alpha-1-Antitrypsin-Deficiency in COVID-19</brief_title>
  <acronym>CORSAAR-AAT</acronym>
  <official_title>Individual Treatment of COVID-19 by Application of Alpha-1-antitrypsin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität des Saarlandes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical&#xD;
      course of patients that received AAT infusion for clinical indication is monitored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical&#xD;
      course of patients that received AAT infusion for clinical indication is monitored. Clinical&#xD;
      outcomes, blood inflammatory markers, and virus load are monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical course</measure>
    <time_frame>3 months</time_frame>
    <description>Disease course such as death, need for ICU treatment, ventilatory support or deterioration are monitored</description>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAT( Alpha 1 Antitrypsin)</intervention_name>
    <description>AAT administration based on clinical indication</description>
    <other_name>AAT administration based on clinical indication</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, RNA, DNA, EDTA plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All COVID-19 patients without need for invasive ventilation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infection with SARS-COV2&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unability to consent&#xD;
&#xD;
          -  Invasive ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bals</last_name>
    <role>Principal Investigator</role>
    <affiliation>UDS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität des Saarlandes</investigator_affiliation>
    <investigator_full_name>Robert Bals</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

